Skip to main content Skip to section navigation Skip to footer
  • Visit us on Facebook
  • Visit us on Twitter
  • Visit us on Linkedin
Kintara Therapeutics, Inc.
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Academic Collaboration
    • Advisors
  • Pipeline
    • Overview
    • REM-001
  • Clinical Trials
  • News & Media
    • Press Releases
    • Publications and Abstracts
    • Presentations
    • Recent News
    • Events
  • Investors
    • Overview
    • Analyst Coverage
    • News & Events
    • Company Info
    • Stock Info
    • SEC Filings
    • Governance
  • Contact
  • Careers

Press Releases

Investors

Investors

  • Overview
  • Analyst Coverage
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Presentations
    • Management Team
    • Contacts
    • FAQ
  • Stock Info
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Independent Directors
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024

October 16, 2024 • 12:54 PM EDT

Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences

October 16, 2024 • 11:58 AM EDT

Kintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024

October 15, 2024 • 4:15 PM EDT

Kintara Therapeutics Announces Record Date for CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024

October 14, 2024 • 8:30 AM EDT

Kintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate Update

October 8, 2024 • 7:00 AM EDT

Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024

September 20, 2024 • 9:25 AM EDT

Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences

September 18, 2024 • 8:30 AM EDT

Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study

September 11, 2024 • 8:30 AM EDT

Kintara Therapeutics to Hold Special Meeting of Stockholders to Allow for Completion of the Proposed Merger with TuHURA Biosciences, Inc.

September 9, 2024 • 8:30 AM EDT

TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer

August 19, 2024 • 9:00 AM EDT
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 37
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
©2025 Kintara Therapeutics, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap Legal Information Manage Cookie Preferences